YM BioSciences Inc YMI

Griffin Sec 5$US target

[greatemailslob]

 

1. ERBITUX® AND VECTIBIX® LIKELY TO BE SUPPLANTED BY YMI’S NIMOTUZUMAB AS THE EGFR MONOCLONAL ANTIBODY OF CHOICE IN A GREAT MAJORITY OF TUMORS. There has been a profound change in the scientific understanding of nimotuzumab, as described in a poster presented at the recent AACR annual meeting entitled, "Binding properties of the anti-EGFR monoclonal antibody nimotuzumab limit its interaction with the EGFR in renal and epidermal cells."1 Nimotuzumab is an affinity-optimized antibody that, by virtue of its lower affinity than the marketed EGFR mAbs, depends on avidity (bivalent binding) for definitive attachment to the receptors, avoids normal tissue, and is clinically effective in those circumstances where there is a moderate-to-high expression of EGF receptor. As demonstrated by YMI, this occurs naturally in high-expressing tumor cells, such as in head and neck, glioma, cervical, and gastric cancers, and also in indications where any radiation-containing treatment is utilized (e.g., NSCLC). The low-expressing tumor cell type tumors other than those treated with radiation-containing regimens are not targets for nimotuzumab. While refractory colorectal cancer would be a low-expressing cancer not amenable to treatment with nimotuzumab, the rectal cancer component (approximately 20%) would fit the radiation-treated category. We believe the implications of these findings and the related value to both cancer patients and shareholders are potentially substantial given that nimotuzumab will prospectively be an important competitor to Erbitux®, whose 2008 sales were $1.5 billion, and for which Eli Lilly (NYSE: LLY) recently acquired ImClone Systems for $6 billion.
2. ? STRONG GLOBAL PARTNERS SUPPORT NIMOTUZUMAB CLINICAL DEVELOPMENT. Nimotuzumab has completed 20 clinical trials around the world, and, notably, nimotuzumab is already approved for sale in India, China, Indonesia, the Philippines and 16 other developing countries, Importantly, the drug is in later stage clinical trials in major global markets with YMI’s licensees, which include Daiichi-Sankyo in Japan, Oncoscience AG in Western Europe, Kuhnil Pharma Co. in Korea, and Innogene Kalbiotech/Kalbe Farma in Singapore. Each licensee is funding clinical trials in their respective regional markets, and YMI is entitled to a royalty on revenue upon commercialization. There are another 32 clinical trials ongoing worldwide in various solid tumors.2
3. ? U.S. GOVERNMENT CLEARS THE WAY FOR NIMOTUZUMAB SOLID TUMOR TRIALS. On August 10, 2009, YMI announced that the Company’s wholly-owned subsidiary YM BioSciences USA, Inc. received permission from the U.S. Department of the Treasury’s Office of Foreign Assets Control (OFAC) to develop nimotuzumab, in solid tumors in the U.S.3 This permission allows YMI to undertake multiple clinical trials in the U.S. and provides positive momentum towards realizing its eventual commercial goals in the U.S. The Company has already commenced discussions with the FDA for permission to include U.S. patients in its current palliative lung cancer and brain metastases from lung cancer trials. The Company has also applied for a license to market nimotuzumab if approved by the FDA, which would be necessary to commercialize the product in the U.S. Plans to commence commercialization discussions with pharmaceutical companies are underway.
4. ? EFFICACY DATA FROM NIMOTUZUMAB’S PHASE IIB TRIAL IN HEAD & NECK CANCER PRESENTED AT ASCO. The Phase IIb ("BEST") randomized clinical trial demonstrated that the efficacy of nimotuzumab compares favorably to results reported for Erbitux® and showed a statistically significant difference in overall survival (p=0.0018) between the arms. Significantly, this randomized trial supports the mechanism data that demonstrates that patients showed essentially 
   1. equivalent clinical benefit from nimotuzumab in high-EGFR expressing cells (SCCHN >80%) without the numerous severe toxicities of Erbitux®.4
   2. ? YMI SHARES REPRESENT EXCEPTIONAL VALUE. Given that the Company is trading near its cash balances of approximately $37 million as of March 31, 2009, nimotuzumab’s recent green light by the U.S. government for its development in the U.S., and the prospect of being best-in-class in an established and currently marketed class of billion dollar drugs, we believe the upside for the nimotuzumab asset and YMI is exceptional. Our valuation model supports a 12-month target price of $5.00 per share; therefore, we reiterate our BUY recommendation on YM BioSciences, Inc. and establish a new 12-month target price of $5.00 per share.

[JuniorIOU]

This is the part Like :)YMI SHARES REPRESENT EXCEPTIONAL VALUE. Given that the Company is trading near its cash balances of approximately $37 million as of March 31, 2009, nimotuzumab’s recent green light by the U.S. government for its development in the U.S., and the prospect of being best-in-class in an established and currently marketed class of billion dollar drugs, we believe the upside for

[JuniorIOU]

We could see $2.50 shortly.  Half way to the target price of $5.00 :)

[greatemailslob]

doubled at 120 my positionup she goes

[JuniorIOU]

$1.50 then .....  The Sky is the limit

[pocotrader]

thanks for the post, I took a position this morning at 1.15 when I noticed the action, added at 1.33 then twice at 1.48, this info just reafirms I made a good choice